Multiple myeloma (MM) remains a heterogeneous disease with diverse molecular and cytogenetic profiles that influence treatment responses and long-term outcomes. The translocation t(11;14), which leads to overexpression of cyclin D1 (CCND1), is the most common primary translocation event in MM, affecting around 16–24% of newly diagnosed myeloma patients 1 . A recent study, the IFM2020-02 MIDAS trial, highlighted the impact of t(11;14) on the depth of response assessed by minimal residual disease (MRD). It demonstrated that MRD-negativity levels after 6 cycles of a quadruplet induction with isatuximab, carfilzomib, lenalidomide and dexamethasone were lower in this subgroup compared with other patients, suggesting a more slower response 2 . However, in many other studies of high-dose therapy, t(11;14) was not associated with worse progression-free survival (PFS) or overall survival (OS) 3 , 4 , 5 , 6 . These findings have prompted further investigation into the clinical significance of t(11;14) and cyclin D1 overexpression in MM, particularly with respect to long-term outcomes.
Perrot et al. (Fri,) studied this question.